The drug would need to be taken long before symptoms first appear—but it could be used to help protect at-risk individuals.

A new preclinical model offers a unique platform for studying the Parkinson's disease process and suggests a relatively easy method for detecting the disease in people. A new preclinical model offers ...

For decades, medical understanding of Parkinson’s disease focused exclusively on the brain, specifically the death of dopamine-producing neurons that control movement. This narrow view shaped ...

As we age, our cells don’t just wear down—they reorganize. Researchers found that cells actively remodel a key structure called the endoplasmic reticulum, reducing protein-producing regions while ...

A work group convened by the Alzheimer's Association has released revised biology-based criteria for the diagnosis and staging of Alzheimer's disease (AD), including a new biomarker classification ...

Please provide your email address to receive an email when new articles are posted on . Ianalumab bested placebo in ESSDAI score at 48 weeks among patients with Sjögren’s disease. Monthly ianalumab ...

Beta-amyloid plaques are considered a hallmark of Alzheimer’s disease, but they’re not the sole cause of the disease and its symptoms. Alzheimer’s is a complicated disease that experts are still ...

Proactive client education and regular physical examinations give veterinarians the opportunity to extend symptom-free time in cases of mitral valve disease, one of the most common cardiac diseases ...

People affected by Huntington’s disease could at last benefit from the first treatment to slow the fatal neurodegenerative condition. Scientists from University College London (UCL) found patients ...